Loading...
Market
Story
Merck's CAPVAXIVE™ ($MRK) Vaccine Shows Positive Results in At-Risk Adults
Oct 16, 2024, 10:51 AM
Merck's CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) has demonstrated positive immune responses in adults with an increased risk for pneumococcal disease. The new Phase 3 data was shared at IDWeek 2024, highlighting the vaccine's efficacy in providing immune protection against pneumococcal disease, a significant concern for at-risk populations. The vaccine's development is a notable achievement for Merck ($MRK).
View original story
Similar markets
Approved in all major markets • 25%
Approved in some major markets • 25%
Not approved in any major markets • 25%
Approval status pending • 25%
<10% • 25%
10-20% • 25%
20-30% • 25%
>30% • 25%
United States • 25%
European Union • 25%
China • 25%
Other • 25%
United States • 25%
European Union • 25%
China • 25%
Other • 25%
Sub-Saharan Africa • 25%
Southeast Asia • 25%
South America • 25%
Other • 25%
0-10 • 25%
11-30 • 25%
31-60 • 25%
61-120 • 25%
United States • 25%
European Union • 25%
India • 25%
Other • 25%
United States • 25%
European Union • 25%
Africa • 25%
Other • 25%